

## **Aerie Pharmaceuticals Inc**

### **CORTELLIS COMPANY DETAILED PIPELINE REPORT**

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 05-Aug-2014

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Phase 2 Clinical..... 14

    Discovery..... 21

[Return to Table of Contents](#)

# Aerie Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	Aerie Pharmaceuticals Inc
Parent Company Name	Aerie Pharmaceuticals Inc
Website	<a href="http://www.aeriepharma.com/">http://www.aeriepharma.com/</a>
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	5
Number of Patents as Owner	12
Number of Patents as Third Party	1
Number of Deals	1
Key Indications	Ocular hypertension, Glaucoma, Angle closure glaucoma, Dermatological disease, Gastrointestinal disease, Ocular disease, Bone disease, Cancer, Obesity, Renal disease
Key Target-based Actions	Rho associated protein kinase inhibitor, Noradrenaline transporter inhibitor, Prostanoid receptor agonist, Rhodopsin kinase inhibitor, Protein kinase modulator
Key Technologies	Small molecule therapeutic, Ophthalmic formulation, Ophthalmic liquid formulation, Solution, Ophthalmic drug implant, Drug combination, Sustained release formulation, Crystalline form, Salt synthesis, Dermatological formulation

## COMPANY PROFILE

### SUMMARY

Aerie Pharmaceuticals Inc, a spin-out of Duke University Medical Center, is a biotechnology company developing therapies for sight-threatening diseases of the eye such as glaucoma. Its discovery platform includes a prodrug technology that increases drug delivery through the cornea.

### EARLY R&D

By November 2007, the company was investigating protein kinase inhibitors and ethacrynic acid derivatives, to lower intraocular pressure in glaucoma patients. At that time, preclinical candidates from the series were anticipated later in that year.

### FINANCIAL

In September 2013, Aerie filed a registration statement on Form S-1 with the US Securities and Exchange Commission, regarding a proposed initial public offering of its common stock. At that time, the company planned to list its common stock on the NASDAQ Global Market under the ticker symbol "AERI". In October 2013, the company priced the offering of 6,720,000 shares of its common stock at a price of US \$10 each. The underwriters were granted a 30-day option to purchase up to an additional 1,008,000 shares of common stock at the same price to cover over-allotments. The offering was expected to close on October 30, 2013; at that time, trading of the shares began; later that month, the offering was closed. Net proceeds of approximately \$68.4 million were expected from the issue of 7,728,000 common stock shares, including 1,008,000 shares from the fully exercised underwriters over-allotment option; later that month, the company raised gross proceeds of \$77.3 million and \$68.3 million after IPO fees and expenses.

In March 2011, Aerie raised \$30 million through a series B financing.

In October 2005, Aerie raised \$21 million through a series A financing.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	4	5	9

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	2
Discovery	1
Discontinued	3
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Delivery/Formulation	0	0	1	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	0	13

[Return to Table of Contents](#)

## Trials by Phase

Phase	Ongoing	All
Phase 2	0	12
Phase 1	0	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	8	0	8
Endocrine disease	2	0	2
Gastrointestinal disease	8	0	8
Genitourinary disease	9	1	10
Degeneration	2	0	2
Andrology	1	0	1
Immune disorder	2	0	2
Musculoskeletal disease	8	0	8
Neoplasm	7	0	7
Ocular disease	11	0	11
Metabolic disorder	1	0	1
Neurological disease	2	0	2
Nutritional disorder	4	0	4
Respiratory disease	7	1	8
Inflammatory disease	8	0	8
Gynecology and obstetrics	1	0	1
Dermatological disease	8	0	8

[Return to Table of Contents](#)





\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### AR-13324

#### AR-13324 SNAPSHOT

Drug Name	AR-13324
Key Synonyms	Rhopressa
Originator Company	Aerie Pharmaceuticals Inc
Active Companies	Aerie Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Ocular hypertension;Glaucoma
Target-based Actions	Rho associated protein kinase inhibitor;Noradrenaline transporter inhibitor
Other Actions	Antiglaucoma agent;Antihypertensive
Technologies	Ophthalmic formulation;Ophthalmic liquid formulation;Solution;Small molecule therapeutic
Last Change Date	24-Jul-2014

#### AR-13324 DEVELOPMENT PROFILE

##### SUMMARY

Aerie Pharmaceuticals is developing Rhopressa (AR-13324), the lead from a series of dual ROCK inhibitor and norepinephrine transporter inhibitor compounds, formulated as a once-daily ophthalmic solution, for the potential treatment of glaucoma and ocular hypertension,. In July 2014, Aerie was planning on seeking to outlicense commercialization rights to the drug for Europe and Japan.

In January 2014, the company planned filing an NDA by mid-2016. In July 2014, three phase III registration trials were initiated.

Aerie is also investigating a fixed dose combination of AR-13324 + latanoprost for the treatment of ocular hypertension.

The company was previously investigating AR-13165, for glaucoma. In October 2009, IND-enabling studies were underway; however in October 2011, AR-13165 was no longer listed on the company's pipeline.

#### AR-13324 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Aerie Pharmaceuticals Inc	Glaucoma	Canada	Phase 3 Clinical	14-Jul-2014
Aerie Pharmaceuticals Inc	Glaucoma	US	Phase 3 Clinical	14-Jul-2014
Aerie Pharmaceuticals Inc	Ocular hypertension	US	Phase 3 Clinical	14-Jul-2014

## AR-13324 DRUG NAMES


Names	Type
AR-13165	Research Code
AR-13324	Research Code
dual-targeting compounds (Glaucoma), Aerie	
Rhopressa	Trade Name
AR-13165 series	

## AR-13324 SALES AND FORECASTS


### CHARTS

[Return to Table of Contents](#)


## Total Sales



### Company Analysis 2017



### Regional Analysis 2017



[Return to Table of Contents](#)

## COMMENTARY

### CONSENSUS SALES INFORMATION

Consensus forecast data for Aerie Pharmaceuticals are presented.

### REGIONAL DEVELOPMENT AND MARKETING RIGHTS

Aerie Pharmaceuticals holds exclusive development and marketing rights.

### AR-13324 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Ocular hypertension											
0	0	0	0	0	3	0	0	0	0	0	3
Open angle glaucoma											
0	0	0	0	0	2	0	0	0	0	0	2

#### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	3	0	1	0	0	0	4

#### Phase Definitions

##### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

##### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

##### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

## AR-12286

### AR-12286 SNAPSHOT

Drug Name	AR-12286
Key Synonyms	
Originator Company	Aerie Pharmaceuticals Inc
Active Companies	Aerie Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Angle closure glaucoma
Target-based Actions	Rho associated protein kinase inhibitor
Other Actions	Antiglaucoma agent;Antihypertensive;Ophthalmological agent
Technologies	Ophthalmic formulation;Ophthalmic liquid formulation;Solution;Small molecule therapeutic
Last Change Date	05-Jun-2014

### AR-12286 DEVELOPMENT PROFILE

#### SUMMARY

Aerie Pharmaceuticals is developing AR-12286, formulated as CF-286-03 or CF-286-04, a Rho kinase (ROCK) inhibitor ophthalmic solution, for the potential treatment of chronic angle-closure glaucoma,. In May 2014, a phase II study was initiated in patients with chronic angle-closure glaucoma, in the US. At that time, the study was expected to be completed in February 2015.

Aerie Pharmaceuticals was developing AR-12286, for the potential treatment of glaucoma including open angle glaucoma and ocular hypertension,. In May 2009, a phase IIa trial in glaucoma was initiated ; in October 2009, results were reported. In February 2010, a phase IIb US study in ocular hypertension was initiated ; in September 2010, positive top-line data were reported ; in October 2011, additional phase IIb studies were ongoing. In February 2013, a phase II study for open angle glaucoma and ocular hypertension was initiated in the US. At that time, the trial was expected to be completed in February 2014. In October 2012, a phase II study for open angle glaucoma and ocular hypertension was initiated in US and India. In June 2013, the company discontinued development of the drug because of limited efficacy.

In January 2009, the company was also investigating an equally potent back-up compound for the potential treatment of additional indications.

### AR-12286 DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Aerie Pharmaceuticals Inc	Angle closure glaucoma	US	Phase 2 Clinical	31-May-2014

[Return to Table of Contents](#)


Company	Indication	Country	Development Status	Date
Aerie Pharmaceuticals Inc	Glaucoma	US	Discontinued	30-Jun-2013
Aerie Pharmaceuticals Inc	Ocular hypertension	India	Discontinued	30-Jun-2013
Aerie Pharmaceuticals Inc	Ocular hypertension	US	Discontinued	30-Jun-2013
Aerie Pharmaceuticals Inc	Open angle glaucoma	India	Discontinued	30-Jun-2013
Aerie Pharmaceuticals Inc	Open angle glaucoma	US	Discontinued	30-Jun-2013

## AR-12286 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
AR-12132	Research Code

CAS Registry Number:	Confidence Level:
	5
	
Name	Type
AR-11236	Research Code

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	5
	
Name	Type
AR-12080	Research Code

### AR-12286 DRUG NAMES

Names	Type
CF-286-04	Research Code
AR-12132	Research Code
AR-11236	Research Code
AR-12286	Research Code
CF-286-03	Research Code
AR-12080	Research Code

### AR-12286 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Glaucoma											
0	0	0	0	1	5	0	1	0	0	1	6
Ocular hypertension											
0	0	0	0	1	4	0	1	0	0	1	5
Open angle glaucoma											
0	0	0	0	0	3	0	0	0	0	0	3

[Return to Table of Contents](#)



Angle closure glaucoma											
0	0	0	0	1	1	0	0	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	2	9	0	1	0	0	2	10

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

## AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie

### AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie SNAPSHOT

<b>Drug Name</b>	AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie
<b>Key Synonyms</b>	Roclatan
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Glaucoma;Ocular hypertension
<b>Target-based Actions</b>	Rho associated protein kinase inhibitor;Noradrenaline transporter inhibitor
<b>Other Actions</b>	Ophthalmological agent;Antihypertensive;PGF2 alpha agonist
<b>Technologies</b>	Drug combination;Ophthalmic formulation;Ophthalmic liquid formulation;Small molecule therapeutic
<b>Last Change Date</b>	26-Jun-2014

### AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie DEVELOPMENT PROFILE

#### SUMMARY

Aerie Pharmaceuticals is developing a quadruple action program, Roclatan (PG-324), a fixed dose combination of triple-action compound AR-13324 (Rhopressa), a ROCK inhibitor and norepinephrine transporter inhibitor and latanoprost, a prostanoid-selective prostaglandin F receptor agonist, formulated as a once-daily, eye drop, for the potential treatment of ocular hypertension and glaucoma. In January 2014, a phase IIb trial was initiated; in June 2014, the trial was completed and positive data were reported. In May 2014, phase III trials were expected to begin in early third quarter 2014; at that time, an NDA filing was expected in mid-2016. In June 2014, the company was planning to commence licensing discussions for commercialization outside of North America.

### AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Aerie Pharmaceuticals Inc	Glaucoma	US	Phase 2 Clinical	30-Jan-2014
Aerie Pharmaceuticals Inc	Ocular hypertension	US	Phase 2 Clinical	30-Jan-2014

### AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
130209-82-4	1
	
Name	Type
latanoprost	BAN; INN; USAN
Catioprost	Trade Name
LatanoSol	Trade Name
Xalatan	Trade Name
PhXA-41	Research Code

#### AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie DRUG NAMES

Names	Type
Roclatan	Trade Name
AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie	
AR-13324 + latanoprost	
PG-324	Research Code

#### AR-13324 + latanoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie CLINICAL TRIALS

##### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Ocular hypertension											
0	0	0	0	0	1	0	0	0	0	0	1
Open angle glaucoma											
0	0	0	0	0	1	0	0	0	0	0	1

[Return to Table of Contents](#)

## Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	0	0	0	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

## AR-13533

### AR-13533 SNAPSHOT

Drug Name	AR-13533
Key Synonyms	
Originator Company	Aerie Pharmaceuticals Inc
Active Companies	Aerie Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Ocular hypertension
Target-based Actions	Noradrenaline transporter inhibitor;Rho associated protein kinase inhibitor
Other Actions	Antihypertensive
Technologies	Ophthalmic formulation;Solution;Small molecule therapeutic
Last Change Date	06-Jun-2014

### AR-13533 DEVELOPMENT PROFILE

#### SUMMARY

Aerie Pharmaceuticals is developing AR-13533, a second-generation dual ROCK and norepinephrine transporter (NET) inhibitor ophthalmic solution for the potential treatment of ocular hypertension. In September 2013, the drug was listed as being in preclinical development.

Aerie is developing the dual ROCK/NET inhibitor AR-13324.

### AR-13533 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Aerie Pharmaceuticals Inc	Ocular hypertension	US	Discovery	17-Sep-2013

### AR-13533 DRUG NAMES

Names	Type
AR-13533	Research Code

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

